Justin Pritchard

Huck Early Career Entrepreneurial Professorship; Assistant Professor of Biomedical Engineering;

Justin Pritchard

Research Summary

Using systems and synthetic biology approaches to understand and control drug resistance.

Huck Graduate Students

Huck Affiliations


Publication Tags

Neoplasms Pharmaceutical Preparations Mutation Therapeutics Infection Genome Infiltration Growth Population Dynamics Platinum Bacteria Tumors Drug Resistance Datasets Epidemiology Pathogens Mycobacterium Resistance Drug Cisplatin Oxaliplatin Drug Combinations Sequence Analysis Genes Tumor

Most Recent Papers

The risks of perpetuating an evolutionary arms race in drug discovery

Scott Leighow, Justin Pritchard, Evolution, Medicine, and Public Health

Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts

Thu Nguyen Anh Tran, Nathan B. Wikle, Emmy Albert, Haider Inam, Emily Strong, Karel Brinda, Scott M. Leighow, Fuhan Yang, Sajid Hossain, Justin R. Pritchard, Philip Chan, William P. Hanage, Ephraim M. Hanks, Maciej F. Boni, 2021, BMC Medicine

Synthesis, structure and anticancer properties of new biotin- and morpholine-functionalized ruthenium and osmium half-sandwich complexes

Mickaël Marloye, Haider Inam, Connor J. Moore, Vinciane Debaille, Justin R. Pritchard, Michel Gelbcke, Franck Meyer, François Dufrasne, Gilles Berger, 2021, Journal of Biological Inorganic Chemistry on p. 535-549

Refined quantification of infection bottlenecks and pathogen dissemination with STAMPR

Karthik Hullahalli, Justin R. Pritchard, Matthew K. Waldor, 2021, mSystems

Preclinical characterization of THE-630, a next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST)

Victor Rivera, Wei-Sheng Huang, Mengrou Lu, Justin Pritchard, David Dalgarno, William Shakespeare, 2021, Cancer Research on p. 1

Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer

Catríona M. Dowling, Kate E.R. Hollinshead, Alessandra Di Grande, Justin Pritchard, Hua Zhang, Eugene T. Dillon, Kathryn Haley, Eleni Papadopoulos, Anita K. Mehta, Rachel Bleach, Andreas U. Lindner, Brian Mooney, Heiko Düssmann, Darran O'Connor, Jochen H.M. Prehn, Kieran Wynne, Michael Hemann, James E. Bradner, Alec C. Kimmelman, Jennifer L. Guerriero, Gerard Cagney, Kwok Kin Wong, Anthony G. Letai, Tríona Ní Chonghaile, 2021, Science advances

Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL

Nicholas J. Short, Hagop Kantarjian, Rashmi Kanagal-Shamanna, Koji Sasaki, Farhad Ravandi, Jorge Cortes, Marina Konopleva, Ghayas C. Issa, Steven M. Kornblau, Guillermo Garcia-Manero, Rebecca Garris, Jake Higgins, Gabriel Pratt, Lindsey N. Williams, Charles C. Valentine, Victor M. Rivera, Justin Pritchard, Jesse J. Salk, Jerald Radich, Elias Jabbour, 2020, Blood Cancer Journal

Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design

Scott M. Leighow, Chuan Liu, Haider Inam, Boyang Zhao, Justin R. Pritchard, 2020, Cell Reports on p. 3951-3963.e4

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning

Peter M. Bruno, Mengrou Lu, Kady A. Dennis, Haider Inam, Connor J. Moore, John Sheehe, Stephen J. Elledge, Michael T. Hemann, Justin R. Pritchard, 2020, Proceedings of the National Academy of Sciences of the United States of America on p. 4053-4060

Evolution of the nonsense-mediated decay pathway is associated with decreased cytolytic immune infiltration

Boyang Zhao, Justin R. Pritchard, 2019, PLoS Computational Biology

Most-Cited Papers

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress

Peter M. Bruno, Yunpeng Liu, Ga Young Park, Junko Murai, Catherine E. Koch, Timothy J. Eisen, Justin R. Pritchard, Yves Pommier, Stephen J. Lippard, Michael T. Hemann, 2017, Nature Medicine on p. 461-471

Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform

Jeremy M. Rock, Forrest F. Hopkins, Alejandro Chavez, Marieme Diallo, Michael R. Chase, Elias R. Gerrick, Justin R. Pritchard, George M. Church, Eric J. Rubin, Christopher M. Sassetti, Dirk Schnappinger, Sarah M. Fortune, 2017, Nature Microbiology

Defining principles of combination drug mechanisms of action

Justin R. Pritchard, Peter M. Bruno, Luke A. Gilberta, Kelsey L. Caprona, Douglas A. Lauffenburger, Michael T. Hemann, 2013, Proceedings of the National Academy of Sciences of the United States of America on p. E170-E179


Justin R. Pritchard, Michael C. Chao, Sören Abel, Brigid M. Davis, Catherine Baranowski, Yanjia J. Zhang, Eric J. Rubin, Matthew K. Waldor, 2014, PLoS Genetics on p. e1004782

High-resolution definition of the Vibrio cholerae essential gene set with hidden Markov model-based analyses of transposon-insertion sequencing data

Michael C. Chao, Justin R. Pritchard, Yanjia J. Zhang, Eric J. Rubin, Jonathan Livny, Brigid M. Davis, Matthew K. Waldor, 2013, Nucleic Acids Research on p. 9033-9048

Addressing genetic tumor heterogeneity through computationally predictive combination therapy

Boyang Zhao, Justin R. Pritchard, Douglas A. Lauffenburger, Michael T. Hemann, 2014, Cancer Discovery on p. 166-174

Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution

Boyang Zhao, Joseph C. Sedlak, Raja Srinivas, Pau Creixell, Justin R. Pritchard, Bruce Tidor, Douglas A. Lauffenburger, Michael T. Hemann, 2016, Cell on p. 234-246

Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus

Laura Laencina, Violaine Dubois, Vincent Le Moigne, Albertus Viljoen, Laleh Majlessi, Justin Pritchard, Audrey Bernut, Laura Piel, Anne Laure Roux, Jean Louis Gaillard, Bérengère Lombard, Damarys Loew, Eric J. Rubin, Roland Brosch, Laurent Kremer, Jean Louis Herrmann, Fabienne Girard-Misguich, 2018, Proceedings of the National Academy of Sciences of the United States of America on p. E1002-E1011

Understanding resistance to combination chemotherapy

Justin R. Pritchard, Douglas A. Lauffenburger, Michael T. Hemann, 2012, Drug Resistance Updates on p. 249-257

Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors

Theresa Baker, Sujata Nerle, Justin Pritchard, Boyang Zhao, Victor M. Rivera, Andrew Garner, Francois Gonzalvez, 2015, Oncotarget on p. 32646-32655